###### Significance of this study

What is already known about this subject?
=========================================

-   Patients with diabetes frequently encounter depression, which may deteriorate glycemic control and increase the risk of chronic diabetic complications.

-   Patients with chronic kidney disease also often experience depression, which has been associated with poorer outcomes.

What are the new findings?
==========================

-   In Japanese patients with type 1 or type 2 diabetes, progression of stage of nephropathy including dialysis stage was associated with increased risk of depression and severity, as evaluated by Patient Health Questionnaire-9 (PHQ-9).

-   The risk of depression reduced in patients undergoing kidney transplantation.

-   Albuminuria was more strongly associated with depression than estimated glomerular filtration rate.

How might these results change the focus of research or clinical practice?
==========================================================================

-   Collaboration with psychiatrists may be essential for diabetologists to reduce the mental and physical burden of patients with diabetic nephropathy.

Introduction {#s1}
============

Patients with diabetes frequently encounter depression,[@R1] which may deteriorate glycemic control[@R2] and increase the risk of chronic diabetic complications. [@R3] Similarly, patients with chronic kidney disease often experience depression,[@R4] which has been associated with increased risk of rapid decline in glomerular filtration rate (GFR), reaching end-stage kidney disease (ESKD) and mortality after the start of dialysis.[@R4] [@R5] In contrast, patients who have undergone kidney transplantation have been shown to be less frequently associated with depression than those undergoing dialysis.[@R6]

Close relationships between diabetic nephropathy and depression are also observed.[@R9] Cohort studies have demonstrated that depression in patients with diabetes leads to increased risk of ESKD.[@R13] However, severity of depression has not been comprehensively examined among the stages of diabetic kidney disease. Moreover, the effects of kidney transplantation on depressive symptoms in patients with diabetes have not been well investigated. We therefore conducted this cross-sectional study to clarify the relationship between stage of nephropathy and likelihood or severity of depression in patients with diabetes including those undergoing dialysis therapy and kidney transplantation. We also examined comparative effects of albuminuria and estimated GFR (eGFR), the two major manifestations of diabetic kidney disease, on depression symptoms.

Research design and methods {#s2}
===========================

Subjects {#s2a}
--------

This was a single-center cross-sectional study, which was conducted as a part of the Diabetes Study from the Center of Tokyo Women\'s Medical University (DIACET), which was established in October 2012 by the DIACET committee (Chair: YU, Secretary: JM), as described previously.[@R12] In the current study, among participants of the DIACET, we included Japanese patients with either type 1 or 2 diabetes (1) whose stage of diabetic kidney disease was identified according to laboratory data obtained within 90 days before and after distribution of the questionnaires, (2) those who had been treated with hemodialysis or peritoneal dialysis, and (3) those who had undergone kidney transplantation with a functioning graft at the time when the questionnaires were distributed. This study was conducted after receiving approval from the Ethics Committee of Tokyo Women\'s Medical University and obtaining informed consent from the participants.

Patient Health Questionnaire {#s2b}
----------------------------

Self-administered questionnaires asking health conditions, treatment status and medications, and comorbidities, as well as including items of the Patient Health Questionnaire-9 (PHQ-9) were distributed to patients at the time of their outpatient visit or admission. The questionnaires were retrieved either at the following outpatient visit or by mail and from inpatients during their hospitalization. The PHQ-9 comprises nine items inquiring about depressive symptoms.[@R14] For each item, respondents choose one of the following responses with reference to the past 2 weeks: 'not at all', 'several days', 'more than half the days', or 'nearly every day'. These options correspond to scores of 0--3 points; the total score for all questions (0--27) was calculated. On the basis of the total score of the nine questions, patients are classified into the following three levels of depression: no depression (0--4 points), mild depression (5--9 points), and moderate or severe depression (10 points or more).

In this study, patients with total scores above 5 and 10 were considered 'mild' and 'moderate-to-severe' depression, respectively.[@R14] The reliability and validity of the Japanese version of the PHQ-9 was validated by Muramatsu *et al*.[@R15]

Definition of stage of diabetic nephropathy {#s2c}
-------------------------------------------

Stage of diabetic nephropathy was classified based on the revised classification proposed by the Joint Committee on Diabetic Nephropathy, consisting of the following four academic societies: the Japan Diabetes Society, the Japanese Society of Nephrology, the Japanese Society for Dialysis Therapy, and the Japan Society of Metabolism and Clinical Nutrition.[@R16] Briefly, stage 1 was defined as normoalbuminuria (\<30 mg/g creatinine) and eGFR≥30 mL/min/1.73 m^2^, stage 2 was defined as microalbuminuria (30--299 mg/g creatinine) and eGFR≥30 mL/min/1.73 m^2^, stage 3 was defined as macroalbuminuria (≥300 mg/g creatinine) and eGFR≥30 mL/min/1.73 m^2^, stage 4 was defined as eGFR\<30 mL/min/1.73 m^2^ regardless of the urinary albumin level, and stage 5 was defined as patients currently undergoing dialysis or having a functioning kidney transplant.

In this study, patients in stage 5 undergoing dialysis and kidney transplantation were analyzed separately. The kidney transplant recipients were limited to those with a functioning kidney graft; therefore, patients who restarted dialysis therapy after losing kidney graft function were classified as patients on dialysis. Patients with type 1 diabetes who underwent simultaneous pancreas and kidney transplantation or pancreas transplantation after kidney transplantation were excluded, as pancreas transplantation may influence depressive symptoms and the number of patients was only six.

Serum and urinary creatinine levels were determined by the enzyme method, urinary albumin by immunonephelometry, and glycated hemoglobin (HbA1c) levels by high-performance liquid chromatography. eGFRs were calculated using the predictive equation for the Japanese proposed by the Japanese Society of Nephrology.[@R17]

Other information related to diabetes {#s2d}
-------------------------------------

The presence or absence and type of diabetes was confirmed by reviewing the medical records. The presence or absence of any stage of diabetic retinopathy, symptoms associated with peripheral polyneuropathy, and history of clinical visits for cardiac diseases, stroke, or gangrene were also asked in the questionnaire.[@R12]

Statistical analysis {#s2e}
--------------------

Continuous data were expressed as an arithmetic mean and SD or geometric mean and 95% CI, with distribution range as required; categorical data were expressed by actual frequency and percentage. Continuous or categorical data among nephropathy stages were compared using Dunnett\'s or Dunn\'s multiple comparisons where stage 1 nephropathy was defined as the reference group. The Cochran-Armitage test was used to test an overall trend.

PHQ-9 scores were compared among the nephropathy stage using analysis of covariance (ANCOVA) after adjustment for clinical findings, including age, gender, diabetes type, HbA1c levels, use of oral medications or injection drugs, presence or absence of diabetic retinopathy, symptoms associated with peripheral polyneuropathy, and history of clinical visits for cardiac diseases, stroke, or gangrene, as covariates. The ORs and 95% CIs for PHQ-9 scores above 5 or 10 according to nephropathy stage were calculated by multivariate logistic analysis after adjustment for the above clinical findings, defining stage 1 nephropathy as the reference group.

Finally, to compare the strength of the relationship with depression between albuminuria and eGFR in patients with stages 1--4 nephropathy, the area under the receiver-operating characteristic curve (AUROC) was compared using the method by DeLong[@R18] among three models including either albuminuria or eGFR, or both albuminuria and eGFR.

All statistical analyses were performed using SAS/STAT V.14.1 (SAS Institute, Cary, North Carolina, USA). Differences were considered statistically significant when p values were \<0.05.

Results {#s3}
=======

Clinical characteristics of subject according to nephropathy stage {#s3a}
------------------------------------------------------------------

Among 8128 individuals who completed the questionnaires between October 2012 and January 2013, individuals with normal or borderline glucose tolerance as well as patients with diabetes other than types 1 and 2 were excluded. Next, from the remaining 8058 patients with type 1 and 2 diabetes, as well as those with missing data on albuminuria, serum creatinine, or HbA1c levels within 90 days before and after the day the questionnaires were distributed (N=5841), those who did not answer more than one of the nine questions in the PHQ-9 (N=314), and patients with type 1 diabetes who underwent simultaneous pancreas--kidney transplantation or pancreas transplantation after kidney transplantation (N=6) were eliminated. Finally, a total of 2212 individuals were included in this study ([figure 1](#BMJDRC2016000310F1){ref-type="fig"}).

![Flow chart showing the number of study participants. DIACET, The Diabetes Study from the Center of Tokyo Women\'s Medical University; DM, diabetes mellitus; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; PHQ-9, Patient Health Questionnaire-9.](bmjdrc2016000310f01){#BMJDRC2016000310F1}

The mean (±SD) age was 60.9±13.7 years and the range was 30--92 years. There were 928 women and 1284 men, 374 patients with type 1 diabetes and 1838 patients with type 2 diabetes; 1297, 317, 120, 251, and 227 patients were classified as having stages 1--5 nephropathy, respectively. Among the patients with stage 5 nephropathy, 184 were undergoing dialysis and the remaining 43 had a functioning kidney graft. Clinical findings and laboratory data according to the stage of diabetic nephropathy are shown in [table 1](#BMJDRC2016000310TB1){ref-type="table"}. Patients with advanced stages of nephropathy were more likely to be men, old, treated with antidiabetic, antihypertensive, and antilipidemic mediations, and were also associated with increased diabetes duration and prevalence of diabetic complications. HbA1c levels were significantly higher in patients with stages 2 and 3 nephropathy but significantly lower in patients undergoing dialysis than in patients with stage 1 nephropathy.

###### 

Clinical characteristics and laboratory data in patients with diabetes classified by stage of nephropathy

                                                                                                                               5             
  ------------------------------ ---------------- --------------------- --------------------------- -------------------------- ------------- ------------
  Men (%)                        52.8             65.6\*                68.3\*                      62.2\*                     69.0\*        60.5
  Age (years)                    59.0±13.9        64.0±12.2\*           62.5±14.1\*                 66.7±13.3\*                60.4±12.0     56.2±9.2
  Type 1 diabetes (%)            21.7             8.5\*                 10.8                        7.6\*                      12.0          27.9
  Diabetes duration (years)      17.2±10.5        19.5±10.9\*           20.0±11.6\*                 21.5±11.1\*                23.8±10.9\*   26.2±8.8\*
  Oral hypoglycemic agents (%)   61.5             74.5\*                70.0                        57.4                       49.5\*        30.2\*
  Injection agents (%)           48.3             48.9                  71.7\*                      71.7\*                     69.6\*        97.7\*
  Antihypertensive agents (%)    36.2             68.5\*                84.2\*                      81.7\*                     28.8          7.0\*
  Antilipemic agents (%)         38.2             42.3                  50.8                        58.2\*                     24.5\*        16.3\*
  Retinopathy (%)                29.8             53.6\*                61.7\*                      69.7\*                     81.0\*        83.7\*
  Neuropathy (%)                 53.5             62.8\*                75.8\*                      78.9\*                     78.0\*        60.5
  Cardiac disease (%)            10.3             16.7                  20.0                        25.9\*                     32.1\*        16.3
  Stroke (%)                     1.4              4.1                   3.3                         3.2                        4.4           2.3
  Gangrene (%)                   0.4              1.3                   3.3                         2.0                        4.9           9.3
  HbA1c (%)                      7.4±1.1          7.7±1.2\*             8.0±1.6\*                   7.2±1.4                    7.1±1.3\*     7.8±1.5
  Urinary ACR (mg/g)             7.9 (7.6--8.2)   81.5\* (75.6--87.9)   912.6\* (784.5 to 1061.8)   631.8\* (558.6 to 958.7)   NA            NA
  Serum creatinine (mg/dL)       0.76±0.18        0.90±0.26\*           1.05±0.32\*                 2.96±1.56\*                NA            NA
  eGFR (ml/min/1.73 m^2^)        74.7±17.3        65.5±19.6\*           58.9±24.6\*                 19.6±7.3\*                 NA            NA

Binary and continuous data were expressed as percentage and mean±SD or geometric mean (95% CI), and compared using Dunn\'s multiple comparison test using rank sums and Dunnett\'s multiple comparison test, respectively. Injection agents included insulin and GLP-1 analogs.

Asterisk (\*) indicates statistical significance versus stage 1.

ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like-peptide1; HbA1c, glycated hemoglobin; NA, not available.

The median dialysis duration in the 184 patients was 4.3 years (range 3 days to 27.5 years). Dialysis modality included hemodialysis in 138 patients, peritoneal dialysis in 9 patients, and combination of hemodialysis and peritoneal dialysis in 1 patient. The median postkidney transplantation time in the 43 kidney-transplanted patients was 4.4 years (range 0.5--21.4 years).

Comparison of PHQ-9 scores and depression frequency according to diabetic nephropathy stage {#s3b}
-------------------------------------------------------------------------------------------

Of the 2212 patients examined, 1387, 501, and 324 patients had total PHQ-9 scores of 0--4 points (no depression), 5--9 points (mild depression), and 10 points or more (moderate or severe depression), respectively. [Figure 2](#BMJDRC2016000310F2){ref-type="fig"} shows PHQ-9 score-based severity classification of depression according to the nephropathy stage. Both the proportions of patients with PHQ-9 scores ≥5 points and those with PHQ-9 scores ≥10 points increased in a stepwise manner from patients in stage 1 to the patients on dialysis in stage 5, and then declined in the kidney-transplanted patients in stage 5 (Cochran-Armitage test for the overall trend: p\<0.001 for both).

![Prevalence of depression severity according to the stage of diabetic nephropathy. The white bar shows both the number and proportion of participants who had total PHQ-9 scores of 0--4 points (no depression), the gray bar shows those who had 5--9 points (mild depression), and the black bar shows those who had 10 points or more (moderate or severe depression) in stages 1--5 undergoing dialysis and stage 5 undergoing kidney transplantation, respectively. PHQ-9, Patient Health Questionnaire-9.](bmjdrc2016000310f02){#BMJDRC2016000310F2}

PHQ-9 scores after adjustment for age, gender, type of diabetes, HbA1c levels, medications, and presence of chronic diabetic complications by ANCOVA were significantly higher in patients in stage 4 and patients on dialysis in stage 5 than in those with stage 1 nephropathy ([table 2](#BMJDRC2016000310TB2){ref-type="table"}). ORs for mild or greater depression, defined as PHQ-9 scores ≥5 points, after adjustment for the demographic variables by multiple logistic regression analysis increased in a stepwise manner from patients in stage 2 nephropathy to patients on dialysis with statistical significance in those in stages 3 and 4, and patients on dialysis in reference to those in stage 1, which declined in patients undergoing transplantation ([table 3](#BMJDRC2016000310TB3){ref-type="table"}). Among the demographic data used as covariates in the multiple logistic regression analysis, those significantly associated with depression other than stage of nephropathy are also listed in [table 3](#BMJDRC2016000310TB3){ref-type="table"}.

###### 

Adjusted PHQ-9 scores in patients with diabetes classified by stage of nephropathy

                        Model 1   Model 2                                             
  --------------------- --------- ------------------- --------- ------ -------------- ---------
  1 (reference)         3.85      3.59 to **−**4.11   −         4.00   3.74 to 4.25   −
  2                     4.11      3.59 to 4.64        0.903     4.05   3.54 to 4.56   1.000
  3                     5.64      4.79 to 6.49        \<0.001   5.12   4.29 to 5.94   0.063
  4                     5.93      5.34 to 6.52        \<0.001   5.64   5.02 to 6.25   \<0.001
  5 (dialysis)          7.02      6.33 to 7.71        \<0.001   6.59   5.79 to 7.39   \<0.001
  5 (transplantation)   6.19      4.76 to 7.61        0.008     5.48   4.09 to 6.88   0.183

Least square mean PHQ-9 scores were calculated using the analysis of covariance in patients with diabetes in each stage of nephropathy (stage 1 nephropathy as the control group) without adjustment (model 1) and with adjustment for age, sex, type of diabetes, HbA1c, use of oral hypoglycemic agents, injections, antihypertensive and antilipemic agents, presence of retinopathy, neuropathy, cardiac disease, stroke, and gangrene (model 2).

HbA1c, glycated hemoglobin; PHQ-9, Patient Health Questionnaire-9.

###### 

ORs for depression severity defined as PHQ-9 scores ≥5 and ≥10 in patients with diabetes classified by stage of nephropathy

                                          PHQ-9 scores ≥5   PHQ-9 scores ≥10                                                                                                   
  --------------------------------------- ----------------- ------------------ --------- ------ -------------- --------- ------ -------------- --------- ------ -------------- ---------
  Stage of diabetic nephropathy                                                                                                                                                
   1 (reference)                          1.00              −                  −         1.00   −              −         1.00   −              −         1.00   −              −
   2                                      1.24              0.96 to 1.61       0.100     1.14   0.85 to 1.52   0.385     1.19   0.80 to 1.74   0.373     1.08   0.72 to 1.64   0.703
   3                                      2.06              1.41 to 3.00       \<0.001   1.55   1.01 to 2.36   0.045     2.46   1.55 to 3.91   \<0.001   1.97   1.17 to 3.34   0.011
   4                                      2.48              1.89 to 3.27       \<0.001   2.21   1.59 to 3.07   \<0.001   2.27   1.60 to 3.22   \<0.001   2.19   1.43 to 3.35   \<0.001
   5 (dialysis)                           3.23              2.36 to 4.44       \<0.001   2.87   1.91 to 4.32   \<0.001   3.80   2.65 to 5.44   \<0.001   3.39   2.13 to 5.39   \<0.001
   5 (transplantation)                    2.17              1.18 to 4.00       0.013     1.67   0.85 to 3.29   0.135     2.91   1.44 to 5.91   0.003     2.28   1.04 to 5.00   0.039
   Age (per 10 years)                                                                    0.76   0.70 to 0.83   \<0.001                                   0.81   0.72 to 0.91   \<0.001
   Gender (men vs women)                                                                 0.70   0.58 to 0.86   \<0.001                                   0.72   0.55 to 0.95   0.017
   HbA1c (per 1.0%)                                                                      1.15   1.06 to 1.24   \<0.001                                   1.22   1.11 to 1.35   \<0.001
   Type of diabetes (type 2 vs 1)                                                        1.00   0.73 to 1.38   1.000                                     0.90   0.59 to 1.36   0.610
   Oral hypoglycemic agents (yes vs no)                                                  1.49   1.17 to 1.89   0.001                                     1.39   1.01 to 1.92   0.042
   Injections (yes vs no)                                                                1.16   0.92 to 1.47   0.205                                     0.99   0.72 to 1.36   0.937
   Antihypertensive agents (yes vs no)                                                   1.04   0.84 to 1.30   0.710                                     0.78   0.58 to 1.07   0.122
   Antilipemic agents (yes vs no)                                                        1.07   0.87 to 1.31   0.540                                     1.27   0.96 to 1.67   0.101
   Retinopathy (yes vs no)                                                               1.24   1.01 to 1.53   0.039                                     1.45   1.09 to 1.92   0.010
   Neuropathy (yes vs no)                                                                2.36   1.91 to 2.91   \<0.001                                   2.62   1.90 to 3.61   \<0.001
   Cardiac disease (yes vs no)                                                           1.46   1.11 to 1.93   0.007                                     1.36   0.95 to 1.95   0.094
   Stroke (yes vs no)                                                                    1.89   1.00 to 3.54   0.049                                     1.99   0.96 to 4.14   0.065
   Gangrene (yes vs no)                                                                  1.83   0.79 to 4.24   0.156                                     1.48   0.62 to 3.55   0.378

ORs were estimated using a multivariate logistic model with stage 1 diabetic nephropathy as the reference group.

HbA1c, glycated hemoglobin; PHQ-9, Patient Health Questionnaire-9.

Comparison of the effects of renal parameters on PHQ-9 scores {#s3c}
-------------------------------------------------------------

To compare the strength of the association of albuminuria and eGFR with depression and its severity in patients with stages 1--4 nephropathy, we performed a multiple linear regression analysis using PHQ-9 scores as the dependent continuous variables, as well as a logistic regression analysis defining PHQ-9 scores ≥5 or ≥10 as dependent binary variables. Albuminuria was significantly associated with higher PHQ-9 scores and the scores ≥5 or ≥10 after adjustment for clinical findings, whereas eGFR was not associated with these outcomes ([table 5](#BMJDRC2016000310TB5){ref-type="table"}).[](#BMJDRC2016000310TB4){ref-type="table"}

###### 

Multiple linear and logistic regression analyses to determine significant associations of urinary ACR and eGFR with PHQ-9 scores and PHQ-9 score ≥5 and ≥10

                                         Linear regression analysis   Logistic regression analysis                                                                     
  -------------------------------------- ---------------------------- ------------------------------ --------- ------ -------------- --------- ------ ---------------- ---------
  Log urinary ACR (per 1 SD)             0.39                         0.13 to 0.65                   0.003     1.20   1.06 to 1.37   0.005     1.22   1.03 to 1.46     0.024
  eGFR (per 1 SD)                        0.02                         --0.27 to −0.30                0.909     0.97   0.84 to 1.12   0.648     1.02   0.84 to 1.23     0.856
  Age (per 10 years)                     −0.57                        −0.76 to −0.38                 \<0.001   0.75   0.68 to 0.83   \<0.001   0.80   0.70 to 0.92     0.001
  Gender (men vs women)                  −0.58                        −1.00 to −0.17                 0.006     0.68   0.55 to 0.83   \<0.001   0.71   0.52 to 0.95     0.022
  HbA1c (per 1.0%)                       0.35                         0.18 to 0.53                   \<0.001   1.15   1.05 to 1.25   0.002     1.24   1.12 to 1.39     \<0.001
  Type of diabetes (type 2 vs 1)         0.09                         −0.60 to 0.77                  0.803     1.06   0.75 to 1.49   0.754     0.94   0.57 to 1.53     0.791
  Oral hypoglycemic agents (yes vs no)   0.39                         −0.11 to 0.90                  0.127     1.46   1.12 to 1.89   0.005     1.19   0.82 to 1.72     0.361
  Injections (yes vs no)                 0.15                         −0.35 to 0.64                  0.560     1.16   0.91 to 1.49   0.235     0.90   0.64 to 1.28     0.574
  Antihypertensive agents (yes vs no)    −0.23                        −0.69 to 0.22                  0.318     1.03   0.82 to 1.30   0.802     0.83   0.59 to 1.16     0.279
  Antilipemic agents (yes vs no)         0.69                         0.25 to 1.12                   0.002     1.12   0.90 to 1.39   0.331     1.43   1.04 to 1.95     0.026
  Retinopathy (yes vs no)                0.81                         0.36 to 1.25                   \<0.001   1.23   0.98 to 1.53   0.069     1.55   1.13 to --2.11   0.006
  Neuropathy (yes vs no)                 1.66                         1.24 to 2.09                   \<0.001   2.26   1.80 to 2.83   \<0.001   2.44   1.72 to 3.74     \<0.001
  Cardiac disease (yes vs no)            0.61                         −0.01 to 1.23                  0.055     1.43   1.05 to 1.95   0.023     1.26   0.81 to 1.95     0.301
  Stroke (yes vs no)                     2.16                         0.73 to 3.58                   0.003     2.58   1.29 to 5.16   0.007     2.33   1.03 to 5.28     0.043
  Gangrene (yes vs no)                   1.29                         −0.88 to 3.47                  0.244     1.14   0.41 to 3.21   0.801     1.41   0.43 to 4.68     0.573

ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; PHQ-9, Patient Health Questionnaire-9.

###### 

AUC of ROC curves for renal parameters predicting depression severity defined as PHQ-9 scores ≥5 and 10

                         PHQ-9 scores ≥5   PHQ-9 scores ≥10                                      
  ---------------------- ----------------- ------------------ --------- ------- ---------------- ---------
  Albuminuria            0.574             0.546 to 0.601     −         0.573   0.532 to 0.614   −
  eGFR                   0.518             0.489 to 0.546     0.001\*   0.510   0.467 to 0.554   0.001\*
  Albuminuria and eGFR   0.580             0.552 to 0.610     0.262     0.573   0.531 to 0.614   0.989

AUC, area under the curve; eGFR, estimated glomerular filtration rate; PHQ-9, Patient Health Questionnaire-9; ROC, receiver-operating characteristic curve.

Finally, receiver-operating characteristic curve analysis was conducted to compare predictability of presence and severity of depression between albuminuria and eGFR. As shown in [table 5](#BMJDRC2016000310TB5){ref-type="table"}, the areas under the curve (AUCs) predicting PHQ-9 scores ≥5 and ≥10 were significantly greater in the model of albuminuria than that of eGFR. Adding eGFR to the albuminuria model yielded no significant difference in the AUC.

Discussion {#s4}
==========

In this single-center cross-sectional study of 2212 Japanese patients with type 1 or 2 diabetes, we have shown that later stages of nephropathy were incrementally associated with higher prevalence and more severe depression. In contrast, patients with a successful kidney graft showed lower PHQ-9 scores and smaller risk of depression than those undergoing dialysis. These results were independent of other demographic variables that may affect depressive symptoms, suggesting that progression of diabetic nephropathy and therapeutic modality for ESKD per se are closely associated with the presence and severity of depression in patients with diabetes. We have also shown that albuminuria was more likely to be associated with depression than decreased eGFR; however, the absolute predictive accuracy of albuminuria was considered modest judging from the AUROC.

Several studies have shown a relationship between diabetic nephropathy and depression;[@R9] however, these studies simply observed the association of depression with the presence of diabetic nephropathy. Detailed information is therefore lacking regarding the relationship of depression with nephropathy stage, microalbuminuria, eGFR, and therapeutic modality for ESKD in patients with diabetes. Among the limited number of studies, the Pathway Study consisting of 4082 US community-dwelling patients with diabetes demonstrated that PHQ-9 scores ≥10 were associated with an up to 1.5-fold increase in adjusted OR of albuminuria.[@R10] In the Diabetes and Aging Study, an ancillary study to the Diabetes Study of Northern California (DISTANCE), the risk of depression defined as PHQ-8 scores ≥10, in which the ninth question assessing suicidal or self-injurious thoughts was eliminated from PHQ-9, was high in patients with reduced eGFR among 5805 patients with diabetes aged 60 years or older.[@R11] Our results are in line with these studies; however, to the best of our knowledge, no previous studies have evaluated prevalence of depression, based on PHQ-9 scores or other items, in each nephropathy stage, including ESKD.

In general patients with ESKD, kidney transplantation has been demonstrated to be less likely associated with depression than chronic dialysis in cross-sectional[@R6] [@R7] and longitudinal studies;[@R8] however, information has been scarce in terms of the effects of kidney transplantation in patients with diabetes on depressive symptoms. This study suggested that risk of depression reduces after successful kidney transplantation also in patients with diabetes. Quality of life (QOL) has been repeatedly shown to be decreased in patients treated with either hemodialysis or peritoneal dialysis, leading to depressive symptoms.[@R19] Therefore, mitigation of depressive symptoms after kidney transplantation as a result of improvement of QOL may be easily inferred. On the other hand, severe depression may decrease the patient\'s motivation for receiving a kidney transplant,[@R20] which may have yielded a selection bias associated with lower prevalence of depression in kidney-transplanted patients in this study. Since this was a cross-sectional study, a longitudinal study over a period before and after kidney transplantation is required.

Similar to the Pathway Study,[@R10] we found a significant association between albuminuria and depression, although unlike the DISTANCE survey,[@R11] we found no significant association between reduced eGFR and depression. These cross-sectional studies, including ours, were unable to clarify the causal relationship of albuminuria and GFR with depression. Nevertheless, it is important to consider the potential mechanisms by which albuminuria and depression are mutually related. As previously reported, depression is bidirectionally associated with diabetes and its complications.[@R1] [@R2] [@R21] [@R22] Thus, there are two potential mechanisms to consider: depression may lead to deterioration of glycemic control in patients with diabetes over a long period of time, which may be involved in onset of nephropathy. Alternatively, complication by nephropathy caused depression due to anxiety regarding future initiation of dialysis, or other reasons.[@R23] Moreover, albuminuria is a known potential risk factor for onset of cardiovascular and cerebrovascular disorders through the cardiorenal link.[@R24] We reported the influence of albuminuria to be stronger than that of eGFR in our previous cohort study.[@R25] Hence, it is also conceivable that cardiovascular or cerebrovascular disorders had already complicated patients with advanced albuminuria, causing depression.[@R26]

Limitations of the methods and results of this study included its cross-sectional study design, preventing assessment of the causal relationship between the progression of nephropathy and the increased risk of depression; likewise, the causal relationship between kidney transplantation and reduced risk of depression. Moreover, since this study was conducted at a single university hospital, its findings cannot be generalized to all patients with diabetes. Selection bias also cannot be ruled out because participation in our DIACET study was voluntary, and fewer patients with depression may have participated in the study. We were unable to obtain data regarding other factors that influence depression including socioeconomical status, access to resources and support system, and uncomfortable symptoms. Finally, while the simplicity of the PHQ-9 is convenient for diagnostic screening of depression in primary care and large-scale studies such as this study, it is known to lead to overdiagnosis of depression when it is used as a self-administered questionnaire.[@R1] Future studies should examine this relationship using more accurate methods to diagnose depression, such as interviews with psychiatric specialists. Nevertheless, there has been no previous report of a detailed examination of this relationship based on nephropathy stage in more than 2000 patients with diabetes.

In conclusion, this study revealed the following findings in a large group of Japanese patients with type 1 or 2 diabetes: progression of stage of nephropathy including dialysis stage was significantly associated with risk of depression and the severity, as evaluated by use of PHQ-9; kidney transplantation was associated with reduced risk of depression compared with dialysis; and albuminuria was more strongly associated with depression than eGFR. Additional longitudinal studies are necessary to verify these causal relationships.[](#SM1){ref-type="supplementary-material"}
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